Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Adrenergic receptor alpha-1 | Starlite/ChEMBL | References |
Rattus norvegicus | Serotonin 2 (5-HT2) receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Serotonin transporter | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 4 nM | Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]-ketanserin in rat cortical membranes | ChEMBL. | 8487257 |
IC50 (binding) | = 4 nM | Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]-ketanserin in rat cortical membranes | ChEMBL. | 8487257 |
IC50 (binding) | = 5 nM | Inhibition of [3H]-peroxitine binding to rat cortical membranes as measure of inhibitory activity towards 5-HT uptake | ChEMBL. | 8487257 |
IC50 (binding) | = 5 nM | Inhibition of [3H]-peroxitine binding to rat cortical membranes as measure of inhibitory activity towards 5-HT uptake | ChEMBL. | 8487257 |
IC50 (binding) | > 100 nM | Binding affinity at alpha1-adrenoreceptor by the inhibition of binding to [3H]-prazosin in rat cortical membranes | ChEMBL. | 8487257 |
IC50 (binding) | > 100 nM | Binding affinity at dopamine receptor D2 by the inhibition of binding to [3H]-spiperone in rat striatal membranes | ChEMBL. | 8487257 |
IC50 (binding) | > 100 nM | Binding affinity at alpha1-adrenoreceptor by the inhibition of binding to [3H]-prazosin in rat cortical membranes | ChEMBL. | 8487257 |
IC50 (binding) | > 100 nM | Binding affinity at dopamine receptor D2 by the inhibition of binding to [3H]-spiperone in rat striatal membranes | ChEMBL. | 8487257 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.